Clinical trials: Cancer Head &Neck
Esophageal Cancer, Gastric Cancer (GC)
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric…
- Conditions
- Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- Trial name
- FAPI-GO (NCT07217704)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 19 sites in United States
- Volunteers
- 200 people
- Sponsor
- SOFIE
Head and Neck Cancer
Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer
The purpose of the trial is to study the safety and efficacy of the Medpulser Electroporation System with bleomycin in the treatment of head and neck cancer.
- Trial name
- NCT00198263
- Testing
- Medpulser Electroporation with Bleomycin
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Inovio Pharmaceuticals
Advanced Solid Tumors, Gastric Cancer
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT02318329
- Testing
- FPA144
- Where
- 26 sites in United States, South Korea and 1 more
- Volunteers
- 79 people
- Sponsor
- Five Prime Therapeutics, Inc.
Breast Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients with solid tumors undergoing routine…
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03735680
- Testing
- ONM-100
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- OncoNano Medicine, Inc.
Solid Tumors
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
- Trial name
- FORTITUDE-301 (NCT05325866)
- Testing
- Bemarituzumab
- Where
- 115 sites in United States, Argentina and 24 more
- Volunteers
- 260 people
- Sponsor
- Amgen
Solid Malignancies, Non-Hodgkin's Lymphoma
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
The purposes of this study are to determine: the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle the side effects of AQ4N when given on the above schedule how much AQ4N is in the…
- Trial name
- NCT00090727
- Testing
- AQ4N
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novacea
Head and Neck Squamous Cell Carcinoma, Skin Cancer
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- NCT05047094
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT), Pembrolizumab
- Where
- 3 sites in Israel
- Volunteers
- 48 people
- Sponsor
- Alpha Tau Medical LTD.
Carcinoma, Squamous Cell
Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate
There is a need for more treatment options for patients with recurrent squamous cell cancer of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that include disruption of the p53 pathway, a…
- Trial name
- NCT00041613
- Testing
- INGN 201
- Where
- 5 sites in United States
- Sponsor
- Introgen Therapeutics
Esophageal Squamous Cell Carcinoma
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced…
- Trial name
- KUNLUN (NCT04550260)
- Testing
- Durvalumab, cisplatin + fluorouracil, cisplatin + capecitabine
- Where
- 133 sites in United States, Belgium and 14 more
- Volunteers
- 640 people
- Sponsor
- AstraZeneca
HNSCC
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with programmed death-ligand 1 (PD-L1) positive (combined positive…
- Trial name
- TACTI-003 (NCT04811027)
- Testing
- eftilagimod alpha, pembrolizumab (KEYTRUDA®)
- Where
- 28 sites in United States, Australia and 7 more
- Volunteers
- 171 people
- Sponsor
- Immutep S.A.S.
Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available.
- Conditions
- Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), HRAS Mutant Tumor, Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor
- Trial name
- NCT02383927
- Testing
- Tipifarnib
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 63 people
- Sponsor
- Kura Oncology, Inc.
Head and Neck Cancer
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in…
- Trial name
- NCT05287113
- Testing
- Retifanlimab, INCAGN02385, INCAGN02390
- Where
- 91 sites in United States, Belgium and 12 more
- Volunteers
- 176 people
- Sponsor
- Incyte Biosciences International Sàrl
Head and Neck Neoplasms
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
NC-6004 is a polymeric micelle containing cisplatin as an active moiety. The nanoparticle provides sustained release of the active moiety and utilizes the enhanced permeability and retention (EPR) effect to target release of…
- Trial name
- NCT02817113
- Testing
- NC-6004, Cetuximab, 5-FU
- Where
- 3 sites in Taiwan
- Volunteers
- 4 people
- Sponsor
- Orient Europharma Co., Ltd.
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Squamous Cell Carcinoma
Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck
This is an open-label, exploratory, biomarker study of intravenous temsirolimus given once weekly for 3 weeks to newly diagnosed, advanced stage head and neck cancer subjects prior to beginning their standard therapy for their…
- Trial name
- NCT00195299
- Testing
- Temsirolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Head and Neck Neoplasms
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage…
- Trial name
- BelieveIT-201 (NCT05980598)
- Testing
- TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 β/γ
- Where
- 65 sites in United States, Georgia and 6 more
- Volunteers
- 27 people
- Sponsor
- Ascendis Pharma A/S
Head and Neck Neoplasms
Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)
Study Objectives: To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck…
- Trial name
- NCT00268671
- Testing
- Docetaxel
- Volunteers
- 45 people
- Sponsor
- Sanofi
Head and Neck Squamous Cell Carcinoma
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
- Trial name
- NCT06163534
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Tempus AI
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.